Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.60 Consensus Target Price from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned a consensus recommendation of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $42.60.

A number of analysts have weighed in on COLL shares. Truist Financial increased their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. HC Wainwright boosted their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $33.46 on Wednesday. The firm has a market cap of $1.08 billion, a PE ratio of 12.97 and a beta of 0.95. Collegium Pharmaceutical has a 52 week low of $21.40 and a 52 week high of $42.29. The firm’s fifty day moving average is $37.51 and its 200-day moving average is $35.27. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.40 by $0.22. The firm had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.13 EPS. Sell-side analysts predict that Collegium Pharmaceutical will post 5.81 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caxton Associates LP acquired a new position in Collegium Pharmaceutical during the 1st quarter valued at about $1,730,000. Foundry Partners LLC bought a new stake in Collegium Pharmaceutical during the second quarter worth $492,000. LSV Asset Management grew its holdings in Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after buying an additional 248,751 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in Collegium Pharmaceutical by 159.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after buying an additional 28,100 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after acquiring an additional 17,942 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.